As of April 26, 2023, around 81.3 percent of the U.S. population had received at least one dose of a COVID-19 vaccination. This statistic shows the percentage of the population in the United States who had been given a COVID-19 vaccination as of April 26, 2023, by state or territory.

As part of an ongoing partnership with the Census Bureau, the National Center for Health Statistics (NCHS) recently added questions to assess the prevalence of post-COVID-19 conditions (long COVID), on the experimental Household Pulse Survey. This 20-minute online survey was designed to complement the ability of the federal statistical system to rapidly respond and provide relevant information about the impact of the coronavirus pandemic in the U.S. Data collection began on April 23, 2020. Beginning in Phase 3.5 (on June 1, 2022), NCHS included questions about the presence of symptoms of COVID that lasted three months or longer. Phase 3.5 will continue with a two-weeks on, two-weeks off collection and dissemination approach. Estimates on this page are derived from the Household Pulse Survey and show the percentage of adults aged 18 and over who a) as a proportion of the U.S. population, the percentage of adults who EVER experienced post-COVID conditions (long COVID). These adults had COVID and had some symptoms that lasted three months or longer; b) as a proportion of adults who said they ever had COVID, the percentage who EVER experienced post-COVID conditions; c) as a proportion of the U.S. population, the percentage of adults who are CURRENTLY experiencing post-COVID conditions. These adults had COVID, had long-term symptoms, and are still experiencing symptoms; d) as a proportion of adults who said they ever had COVID, the percentage who are CURRENTLY experiencing post-COVID conditions; and e) as a proportion of the U.S. population, the percentage of adults who said they ever had COVID.

As of June 13, 2023, there have been almost 768 million cases of coronavirus (COVID-19) worldwide. The disease has impacted almost every country and territory in the world, with the United States confirming around 16 percent of all global cases.

COVID-19: An unprecedented crisis Health systems around the world were initially overwhelmed by the number of coronavirus cases, and even the richest and most prepared countries struggled. In the most vulnerable countries, millions of people lacked access to critical life-saving supplies, such as test kits, face masks, and respirators. However, several vaccines have been approved for use, and more than 13 billion vaccine doses had already been administered worldwide as of March 2023.

The coronavirus in the United Kingdom Over 202 thousand people have died from COVID-19 in the UK, which is the highest number in Europe. The tireless work of the National Health Service (NHS) has been applauded, but the country’s response to the crisis has drawn criticism. The UK was slow to start widespread testing, and the launch of a COVID-19 contact tracing app was delayed by months. However, the UK’s rapid vaccine rollout has been a success story, and around 53.7 million people had received at least one vaccine dose as of July 13, 2022.

The New York Times is releasing a series of data files with cumulative counts of coronavirus cases in the United States, at the state and county level, over time. We are compiling this time series data from state and local governments and health departments in an attempt to provide a complete record of the ongoing outbreak.

Since late January, The Times has tracked cases of coronavirus in real time as they were identified after testing. Because of the widespread shortage of testing, however, the data is necessarily limited in the picture it presents of the outbreak.

We have used this data to power our maps and reporting tracking the outbreak, and it is now being made available to the public in response to requests from researchers, scientists and government officials who would like access to the data to better understand the outbreak.

The data begins with the first reported coronavirus case in Washington State on Jan. 21, 2020. We will publish regular updates to the data in this repository.

Based on a comparison of coronavirus deaths in 210 countries relative to their population, Peru had the most losses to COVID-19 up until July 13, 2022. As of the same date, the virus had infected over 557.8 million people worldwide, and the number of deaths had totaled more than 6.3 million. Note, however, that COVID-19 test rates can vary per country. Additionally, big differences show up between countries when combining the number of deaths against confirmed COVID-19 cases. The source seemingly does not differentiate between "the Wuhan strain" (2019-nCOV) of COVID-19, "the Kent mutation" (B.1.1.7) that appeared in the UK in late 2020, the 2021 Delta variant (B.1.617.2) from India or the Omicron variant (B.1.1.529) from South Africa.

The difficulties of death figures

This table aims to provide a complete picture on the topic, but it very much relies on data that has become more difficult to compare. As the coronavirus pandemic developed across the world, countries already used different methods to count fatalities, and they sometimes changed them during the course of the pandemic. On April 16, for example, the Chinese city of Wuhan added a 50 percent increase in their death figures to account for community deaths. These deaths occurred outside of hospitals and went unaccounted for so far. The state of New York did something similar two days before, revising their figures with 3,700 new deaths as they started to include “assumed” coronavirus victims. The United Kingdom started counting deaths in care homes and private households on April 29, adjusting their number with about 5,000 new deaths (which were corrected lowered again by the same amount on August 18). This makes an already difficult comparison even more difficult. Belgium, for example, counts suspected coronavirus deaths in their figures, whereas other countries have not done that (yet). This means two things. First, it could have a big impact on both current as well as future figures. On April 16 already, UK health experts stated that if their numbers were corrected for community deaths like in Wuhan, the UK number would change from 205 to “above 300”. This is exactly what happened two weeks later. Second, it is difficult to pinpoint exactly which countries already have “revised” numbers (like Belgium, Wuhan or New York) and which ones do not. One work-around could be to look at (freely accessible) timelines that track the reported daily increase of deaths in certain countries. Several of these are available on our platform, such as for Belgium, Italy and Sweden. A sudden large increase might be an indicator that the domestic sources changed their methodology.

Where are these numbers coming from?

The numbers shown here were collected by Johns Hopkins University, a source that manually checks the data with domestic health authorities. For the majority of countries, this is from national authorities. In some cases, like China, the United States, Canada or Australia, city reports or other various state authorities were consulted. In this statistic, these separately reported numbers were put together. For more information or other freely accessible content, please visit our dedicated Facts and Figures page.

As of December 23, 2022, around 80 percent of the population of the United States had been given at least one dose of a COVID-19 vaccination. This statistic shows the percentage of population in select countries and territories worldwide that had received a COVID-19 vaccination as of December 23, 2022.

NOTE: As of 2/16/2023, this table is no longer being updated. For data on COVID-19 Updated (Bivalent) Booster Coverage by Age go to https://data.ct.gov/Health-and-Human-Services/COVID-19-Updated-Bivalent-Booster-Coverage-By-Age-/j2me-7k56. For information on COVID-19 vaccination primary series coverage for people less than 5 years go to https://data.ct.gov/Health-and-Human-Services/COVID-19-Vaccination-Primary-Series-Coverage-Age-L/su9q-qn6e Important change as of June 1, 2022 As of June 1, 2022, we will be using 2020 DPH provisional census estimates* to calculate vaccine coverage percentages for state- and county-level tables (except coverage by CT SVI priority zip code). 2020 estimates will replace the 2019 estimates that have been used. Caution should be taken when making comparisons of percentages calculated using the 2019 and 2020 census estimates since observed difference may result from the shift in the denominator. The age groups in the state-level data tables will also be changing as a result of the switch to the new denominator. DPH Provisional State and County Characteristics Estimates April 1, 2020. Hayes L, Abdellatif E, Jiang Y, Backus K (2022) Connecticut DPH Provisional April 1, 2020 State Population Estimates by 18 age groups, sex, and 6 combined race and ethnicity groups. Connecticut Department of Public Health, Health Statistics & Surveillance, SAR, Hartford, CT. This tables shows the number and percent of people that have initiated COVID-19 vaccination, are fully vaccinated, and addition dose 1 by age group. Age is based on age at the time of administration of the first dose. All data in this report are preliminary; data for previous dates will be updated as new reports are received, and data errors are corrected. Population size estimates are based on 2019 DPH census estimates until 5/26/2022. From 6/1/2022, 2020 DPH provisional census estimates are used. In the data shown here, a person who has received at least one dose of COVID-19 vaccine is considered to have initiated vaccination. A person is considered fully vaccinated if he/she has completed a primary vaccination series by receiving 2 doses of the Pfizer, Novavax or Moderna vaccines or 1 dose of the Johnson & Johnson vaccine. The fully vaccinated are a subset of the people who have received at least one dose. A person who completed a Pfizer, Moderna, Novavax or Johnson & Johnson primary series (as defined above) and then had an additional monovalent dose of COVID-19 vaccine is considered to have had additional dose 1. The additional dose may be Pfizer, Moderna, Novavax or Johnson & Johnson and may be a different type from the primary series. For people who had a primary Pfizer or Moderna series, additional dose 1 was counted starting August 18th, 2021. For people with a Johnson & Johnson primary series additional dose 1 was counted starting October 22nd, 2021. For most people, additional dose 1 is a booster. However, additional dose 1 may represent a supplement to the primary series for a people who is moderately or severely immunosuppressed. Bivalent booster administrations are not included in the additional dose 1 calculations. The percent with at least one dose many be over-estimated, and the percent fully vaccinated and with additional dose 1 may be under-estimated because of vaccine administration records for individuals that cannot be linked because of differences in how names or date of birth are reported. Town-level coverage estimates have been capped at 100%. Observed coverage may be greater than 100% for multiple reasons, including census denominator data not including all individuals that currently reside in the town (e.g., part time residents, change in population size since the census), errors in address data or other reporting errors. Also, the percent with at least one dose many be over-estimated, and the percent fully

As of May 2, 2023, there were roughly 687 million global cases of COVID-19. Around 660 million people had recovered from the disease, while there had been almost 6.87 million deaths. The United States, India, and Brazil have been among the countries hardest hit by the pandemic.

The various types of human coronavirus The SARS-CoV-2 virus is the seventh known coronavirus to infect humans. Its emergence makes it the third in recent years to cause widespread infectious disease following the viruses responsible for SARS and MERS. A continual problem is that viruses naturally mutate as they attempt to survive. Notable new variants of SARS-CoV-2 were first identified in the UK, South Africa, and Brazil. Variants are of particular interest because they are associated with increased transmission.

Vaccination campaigns Common human coronaviruses typically cause mild symptoms such as a cough or a cold, but the novel coronavirus SARS-CoV-2 has led to more severe respiratory illnesses and deaths worldwide. Several COVID-19 vaccines have now been approved and are being used around the world.

According to a survey conducted from August 20 to September 16, 2024, approximately 35 percent of U.S. adults aged between 50 and 59 years who had COVID-19 experienced Long COVID, the highest share compared to other age groups. Individuals aged 40 to 49 followed, with 34 percent experiencing Long COVID symptoms. This statistic shows the percentage of adults who had COVID-19 and ever experienced Long COVID in the United States from August 20 to September 16, 2024, by age group.

NOTE: As of 2/16/2023 this table is no longer being updated. For information on COVID-19 Updated (Bivalent) Booster Coverage, go to https://data.ct.gov/Health-and-Human-Services/COVID-19-Updated-Bivalent-Booster-Coverage-By-Race/8267-bg4w. Important change as of June 1, 2022 As of June 1, 2022, we will be using 2020 DPH provisional census estimates* to calculate vaccine coverage percentages by age at the state level. 2020 estimates will replace the 2019 estimates that have been used. Caution should be taken when making comparisons of percentages calculated using the 2019 and 2020 census estimates since observed difference may result from the shift in the denominator. The age groups in the state-level data tables will also be changing as a result of the switch to the new denominator. DPH Provisional State and County Characteristics Estimates April 1, 2020. Hayes L, Abdellatif E, Jiang Y, Backus K (2022) Connecticut DPH Provisional April 1, 2020 State Population Estimates by 18 age groups, sex, and 6 combined race and ethnicity groups. Connecticut Department of Public Health, Health Statistics & Surveillance, SAR, Hartford, CT. This table shows the number and percent of people that have initiated COVID-19 vaccination, are fully vaccinated and had additional dose 1 by race / ethnicity and age group. All data in this report are preliminary; data for previous dates will be updated as new reports are received and data errors are corrected. The age groups in the state-level data tables will also be changing as a result of the switch to the new denominator. Population size estimates are based on 2019 DPH census estimates until 5/26/2022. From 6/1/2022, 2020 DPH provisional census estimates are used. In the data shown here, a person who has received at least one dose of COVID-19 vaccine is considered to have initiated vaccination. A person is considered fully vaccinated if he/she has completed a primary vaccination series by receiving 2 doses of the Pfizer, Novavax or Moderna vaccines or 1 dose of the Johnson & Johnson vaccine. The fully vaccinated are a subset of the people who have received at least one dose. A person who completed a Pfizer, Moderna, Novavax or Johnson & Johnson primary series (as defined above) and then had an additional monovalent dose of COVID-19 vaccine is considered to have had additional dose 1. The additional dose may be Pfizer, Moderna, Novavax or Johnson & Johnson and may be a different type from the primary series. For people who had a primary Pfizer or Moderna series, additional dose 1 was counted starting August 18th, 2021. For people with a Johnson & Johnson primary series additional dose 1 was counted starting October 22nd, 2021. For most people, additional dose 1 is a booster. However, additional dose 1 may represent a supplement to the primary series for a people who is moderately or severely immunosuppressed. Bivalent booster administrations are not included in the additional dose 1 calculations. The percent with at least one dose many be over-estimated, and the percent fully vaccinated and with additional dose 1 may be under-estimated because of vaccine administration records for individuals that cannot be linked because of differences in how names or date of birth are reported. Race and ethnicity data may be self-reported or taken from an existing electronic health care record. Reported race and ethnicity information is used to create a single race/ethnicity variable. People with Hispanic ethnicity are classified as Hispanic regardless of reported race. People with a missing ethnicity are classified as non-Hispanic. People with more than one race are classified as multiple races. A vaccine coverage percentage cannot be calculated for people classified as NH Other race or NH Unknown race since there are not population size estimates for these groups. Data quality assurance activities sug

NOTE: This dataset has been retired and marked as historical-only. The recommended dataset to use in its place is https://data.cityofchicago.org/Health-Human-Services/COVID-19-Vaccination-Coverage-Citywide/6859-spec. COVID-19 vaccinations administered to Chicago residents based on the reported race-ethnicity and age group of the person vaccinated, as provided by the medical provider in the Illinois Comprehensive Automated Immunization Registry Exchange (I-CARE). Vaccination Status Definitions: ·People with at least one vaccine dose: Number of people who have received at least one dose of any COVID-19 vaccine, including the single-dose Johnson & Johnson COVID-19 vaccine. ·People with a completed vaccine series: Number of people who have completed a primary COVID-19 vaccine series. Requirements vary depending on age and type of primary vaccine series received. ··People with an original booster dose: Number of people who have a completed vaccine series and have received at least one additional monovalent dose. This includes people who received a monovalent booster dose and immunocompromised people who received an additional primary dose of COVID-19 vaccine. Monovalent doses were created from the original strain of the virus that causes COVID-19. People with a bivalent dose: Number of people who received a bivalent (updated) dose of vaccine. Updated, bivalent doses became available in Fall 2022 and were created with the original strain of COVID-19 and newer Omicron variant strains. Weekly cumulative totals by vaccination status are shown for each combination of race-ethnicity and age group. Note that each age group has a row where race-ethnicity is "All" so care should be taken when summing rows. Vaccinations are counted based on the date on which they were administered. Weekly cumulative totals are reported from the week ending Saturday, December 19, 2020 onward (after December 15, when vaccines were first administered in Chicago) through the Saturday prior to the dataset being updated. Population counts are from the U.S. Census Bureau American Community Survey (ACS) 2019 1-year estimates. For some of the age groups by which COVID-19 vaccine has been authorized in the United States, race-ethnicity distributions were specifically reported in the ACS estimates. For others, race-ethnicity distributions were estimated by the Chicago Department of Public Health (CDPH) by weighting the available race-ethnicity distributions, using proportions of constituent age groups. Coverage percentages are calculated based on the cumulative number of people in each population subgroup (age group by race-ethnicity) who have each vaccination status as of the date, divided by the estimated number of Chicago residents in each subgroup. Actual counts may exceed population estimates and lead to >100% coverage, especially in small race-ethnicity subgroups of each age group. All coverage percentages are capped at 99%. All data are provisional and subject to change. Information is updated as additional details are received and it is, in fact, very common for recent dates to be incomplete and to be updated as time goes on. At any given time, this dataset reflects data currently known to CDPH. Numbers in this dataset may differ from other public sources due to when data are reported and how City of Chicago boundaries are defined. CDPH uses the most complete data available to estimate COVID-19 vaccination coverage among Chicagoans, but there are several limitations that impact our estimates. Data reported in I-CARE only include doses administered in Illinois and some doses administered outside of Illinois reported historically by Illinois providers. Doses administered by the federal Bureau of Prisons and Department of Defense are also not currently reported in I-CARE. The Veterans Health Administration began reporting doses in I-CARE beginning September 2022. Due to people receiving vaccinations that are not recorded in I-CARE that c

NOTE: As of 2/16/2023, this page is not being updated. This tables shows the number and percent of people that have initiated COVID-19 vaccination, are fully vaccinated and had additional dose 1 grouped by whether they live in an SVI Priority Zip Code. People with an out-of-state zip code are excluded from this analysis. All data in this report are preliminary; data for previous dates will be updated as new reports are received and data errors are corrected. A person who has received at least one dose of any COVID-19 vaccine is considered to have initiated vaccination. A person is considered fully vaccinated if they have completed a primary vaccine series by receiving 2 doses of the Pfizer, Novavax or Moderna vaccines or 1 dose of the Johnson & Johnson vaccine. The fully vaccinated are a subset of the number who have received at least one dose. A person who completed a Pfizer, Moderna, Novavax or Johnson & Johnson primary series (as defined above) and then had an additional dose of COVID-19 vaccine is considered to have had additional dose 1. The additional monovalent dose may be Pfizer, Moderna, Novavax or Johnson & Johnson and may be a different type from the primary series. For people who had a primary Pfizer or Moderna series, additional dose 1 was counted starting August 18th, 2021. For people with a Johnson & Johnson primary series additional dose 1 was counted starting October 22nd, 2021. For most people, additional dose 1 is a booster. However, additional dose 1 may represent a supplement to the primary series for a people who is moderately or severely immunosuppressed. Bivalent booster administrations are not included in the additional dose 1 calculations. SVI refers to the CDC's Social Vulnerability Index - a measure that combines 15 demographic variables to identify communities most vulnerable to negative health impacts from disasters and public health crises. Measures of social vulnerability include socioeconomic status, household composition, disability, race, ethnicity, language, and transportation limitations - among others. SVI scores were calculated for each zip code in CT. The zip codes in the top 20% were designated as SVI Priority Zip Codes. Percentages are based on 2018 zip code population data supplied by ESRI corporation. The percent with at least one dose many be over-estimated and the percent fully vaccinated and with additional dose 1 may be under-estimated because of vaccine administration records for individuals that cannot be linked because of differences in how names or date of birth are reported. Connecticut COVID-19 Vaccine Program providers are required to report information on all COVID-19 vaccine doses administered to CT WiZ, the Connecticut Immunization Information System. Data on doses administered to CT residents out-of-state are being added to CT WiZ jurisdiction-by-jurisdiction. Doses administered by some Federal entities (including Department of Defense, Department of Correction, Department of Veteran’s Affairs, Indian Health Service) are not yet reported to CT WiZ.  Data reported here reflect the vaccination records currently reported to CT WiZ. Note: As part of continuous data quality improvement efforts, duplicate records were removed from the COVID-19 vaccination data during the weeks of 4/19/2021 and 4/26/2021.

As of March 10, 2023, the state with the highest number of COVID-19 cases was California. Almost 104 million cases have been reported across the United States, with the states of California, Texas, and Florida reporting the highest numbers.

From an epidemic to a pandemic The World Health Organization declared the COVID-19 outbreak a pandemic on March 11, 2020. The term pandemic refers to multiple outbreaks of an infectious illness threatening multiple parts of the world at the same time. When the transmission is this widespread, it can no longer be traced back to the country where it originated. The number of COVID-19 cases worldwide has now reached over 669 million.

The symptoms and those who are most at risk Most people who contract the virus will suffer only mild symptoms, such as a cough, a cold, or a high temperature. However, in more severe cases, the infection can cause breathing difficulties and even pneumonia. Those at higher risk include older persons and people with pre-existing medical conditions, including diabetes, heart disease, and lung disease. People aged 85 years and older have accounted for around 27 percent of all COVID-19 deaths in the United States, although this age group makes up just two percent of the U.S. population

As of April 26, 2023, the number of both confirmed and presumptive positive cases of the COVID-19 disease reported in the United States had reached over 104 million with over 1.1 million deaths reported among these cases.

Coronavirus deaths by age in the U.S. Daily new cases of COVID-19 hit record highs in the United States at the beginning of 2022. Underlying health conditions can worsen cases of coronavirus, and case fatality rates among confirmed COVID-19 patients increase with age. The highest number of deaths from COVID-19 have been among those aged 85 years and older, with this age group accounting for over 300 thousand deaths.

Where has this coronavirus come from? Coronaviruses are a large group of viruses transmitted between animals and people that cause illnesses ranging from the common cold to more severe diseases. The novel coronavirus that is currently infecting humans was already circulating among certain animal species. The first human case of this new coronavirus strain was reported in China at the end of December 2019. The coronavirus was named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and its associated disease is known as COVID-19.

These tables will stop being updated after June 1, 2023. COVID-19 vaccination reporting is expected to resume when a new COVID-19 vaccination formulation is authorized. As 4/22/2023, CDC recommends bivalent vaccine for everyone regardless of age and whether or not the person has had prior monovalent vaccine. This table shows the cumulative number and percentage of people who have received an updated (bivalent) COVID-19 vaccination by race/ethnicity and age group for people 5 years and over. • Data are reported weekly on Thursday and include doses administered to Saturday of the previous week. • All data in this report are preliminary. Data for previous weeks may be changed because of delays in reporting, deduplication, or correction of errors. • The table groups people based on their current age and excludes people known to be deceased. • The analyses here are based on data reported to CT WiZ which is the immunization information system for CT. Connecticut COVID-19 Vaccine Program providers are required to report to CT WiZ all COVID-19 doses administered in CT including to CT residents and to residents of other jurisdictions. CT Wiz also receives records on CT residents vaccinated in other jurisdictions and by federal entities which share data with CT WiZ electronically (currently: RI, NJ, New York City, DE, Philadelphia, NV, Indian Health Service, Department of Veterans Affairs (doses administered since 11/2022)). Electronic data exchange is being added jurisdiction-by-jurisdiction. Once a jurisdiction is added to CT WiZ, the records for residents of that jurisdiction vaccinated in CT are removed. For example, when CT residents vaccinated in NYC were added, NYC residents vaccinated in CT were removed. • Population size estimates used to calculate cumulative percentages are based on 2020 DPH provisional census estimates*. • Race and ethnicity data may be self-reported or taken from an existing electronic health care record. Reported race and ethnicity information is used to create a single race/ethnicity variable. People with Hispanic ethnicity are classified as Hispanic regardless of reported race. People with a missing ethnicity are classified as non-Hispanic. People with more than one race are classified as multiple races. A vaccine coverage percentage cannot be calculated for people classified as NH (non-Hispanic) Other race or NH Unknown race since there are no population size estimates for these groups. Data quality assurance activities suggest that in at least some cases NH Other may represent a missing value. Vaccine coverage estimates in specific race/ethnicity groups may be underestimated as result of the classification of records as NH Unknown Race or NH Other Race. • Cumulative percentage estimates have been capped at 100%. Observed percentages may be higher than 100% for multiple reasons, inaccuracies in the census denominators or reporting errors. DPH Provisional State and County Characteristics Estimates April 1, 2020. Hayes L, Abdellatif E, Jiang Y, Backus K (2022) Connecticut DPH Provisional April 1, 2020, State Population Estimates by 18 age groups, sex, and 6 combined race and ethnicity groups. Connecticut Department of Public Health, Health Statistics & Surveillance, SAR, Hartford, CT.

NOTE: As of 2/16/2023, This page is not being updated, for data on COVID-19 Updated (Bivalent) Booster Coverage go to https://data.ct.gov/Health-and-Human-Services/COVID-19-Updated-Bivalent-Booster-Coverage-By-Town/bqd5-4jgh. Important change as of June 1, 2022 As of June 1, 2022, we will be using 2020 DPH provisional census estimates* to calculate vaccine coverage percentages at the county level. 2020 estimates will replace the 2019 estimates that have been used. Caution should be taken when making comparisons of percentages calculated using the 2019 and 2020 census estimates since observed difference may result from the shift in the denominator. DPH Provisional State and County Characteristics Estimates April 1, 2020. Hayes L, Abdellatif E, Jiang Y, Backus K (2022) Connecticut DPH Provisional April 1, 2020, State Population Estimates by 18 age groups, sex, and 6 combined race and ethnicity groups. Connecticut Department of Public Health, Health Statistics & Surveillance, SAR, Hartford, CT. This tables shows the number and percent of people that have initiated COVID-19 vaccination, are fully vaccinated and had additional dose 1 by county of residence. All data in this report are preliminary; data for previous dates will be updated as new reports are received and data errors are corrected. Population size estimates are based on 2019 DPH census estimates until 5/26/2022. From 6/1/2022, 2020 DPH provisional census estimates are used. A person who has received at least one dose of any COVID-19 vaccine is considered to have initiated vaccination. A person is considered fully vaccinated if they have completed a primary series by receiving 2 doses of the Pfizer, Novavax or Moderna vaccines or 1 dose of the Johnson & Johnson vaccine. The fully vaccinated are a subset of the number who have initiated vaccination. Percentages are calculated using 2019 census data (https://portal.ct.gov/DPH/Health-Information-Systems--Reporting/Population/Annual-Town-and-County-Population-for-Connecticut). A person who completed a Pfizer, Moderna, Novavax or Johnson & Johnson primary series (as defined above) and then had an additional monovalent dose of COVID-19 vaccine is considered to have had additional dose 1. The additional dose may be Pfizer, Moderna, Novavax or Johnson & Johnson and may be a different type from the primary series. For people who had a primary Pfizer or Moderna series, additional dose 1 was counted starting August 18th, 2021. For people with a Johnson & Johnson primary series additional dose 1 was counted starting October 22nd, 2021. For most people, additional dose 1 is a booster. However, additional dose 1 may represent a supplement to the primary series for a people who is moderately or severely immunosuppressed. Bivalent booster administrations are not included in the additional dose 1 calculations. The percent with at least one dose may be over-estimated and the percent fully and additional dose 1 vaccinated may be under-estimated because of vaccine administration records for individuals that cannot be linked because of differences in how names or date of birth are reported. County of residence is determined based on the town of residence. Town of residence is verified by geocoding the reported address and then mapping it to a town using municipal boundaries. If an address cannot be geocoded, the reported town is used, if available. Out-of-state residents vaccinated by CT providers excluded from this table. People for whom an address is not currently available are shown in this table as “Address pending validation”. Connecticut COVID-19 Vaccine Program providers are required to report information on all COVID-19 vaccine doses administered to CT WiZ, the Connecticut Immunization Information System. Data on doses administered to CT residents out-of-state are being added to CT WiZ jurisdiction-by-jurisdiction.

This dataset provides the cumulative number and percent of people who have received a COVID-19 vaccine by vaccine product, number of doses, and report week. Variables include: - Report week number - Report week - Cumulative number vaccinated with at least 1 dose - Cumulative number vaccinated with only 1 dose - Cumulative number vaccinated with 2 doses - Cumulative proportion vaccinated with at least 1 dose - Cumulative proportion vaccinated with only 1 dose - Cumulative proportion vaccinated with 2 doses For variable definitions, see the data dictionary. For details regarding data sources and limitations, see the technical notes section of the Canadian COVID-19 vaccination coverage report (https://health-infobase.canada.ca/covid-19/vaccination-coverage/technical-notes.html).

Data for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Vaccination Status. Click 'More' for important dataset description and footnotes

Dataset and data visualization details: These data were posted on October 21, 2022, archived on November 18, 2022, and revised on February 22, 2023. These data reflect cases among persons with a positive specimen collection date through September 24, 2022, and deaths among persons with a positive specimen collection date through September 3, 2022.

Vaccination status: A person vaccinated with a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. Additional or booster dose: A person vaccinated with a primary series and an additional or booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after receipt of an additional or booster dose of any COVID-19 vaccine on or after August 13, 2021. For people ages 18 years and older, data are graphed starting the week including September 24, 2021, when a COVID-19 booster dose was first recommended by CDC for adults 65+ years old and people in certain populations and high risk occupational and institutional settings. For people ages 12-17 years, data are graphed starting the week of December 26, 2021, 2 weeks after the first recommendation for a booster dose for adolescents ages 16-17 years. For people ages 5-11 years, data are included starting the week of June 5, 2022, 2 weeks after the first recommendation for a booster dose for children aged 5-11 years. For people ages 50 years and older, data on second booster doses are graphed starting the week including March 29, 2022, when the recommendation was made for second boosters. Vertical lines represent dates when changes occurred in U.S. policy for COVID-19 vaccination (details provided above). Reporting is by primary series vaccine type rather than additional or booster dose vaccine type. The booster dose vaccine type may be different than the primary series vaccine type. ** Because data on the immune status of cases and associated deaths are unavailable, an additional dose in an immunocompromised person cannot be distinguished from a booster dose. This is a relevant consideration because vaccines can be less effective in this group. Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Rates of COVID-19 deaths by vaccination status are reported based on when the patient was tested for COVID-19, not the date they died. Deaths usually occur up to 30 days after COVID-19 diagnosis. Participating jurisdictions: Currently, these 31 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (New York), North Carolina, Philadelphia (Pennsylvania), Rhode Island, South Dakota, Tennessee, Texas, Utah, Washington, and West Virginia; 30 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 72% of the total U.S. population and all ten of the Health and Human Services Regions. Data on cases

NOTE: This dataset replaces a previous one. Please see below. Chicago residents who are up to date with COVID-19 vaccines by ZIP Code, based on the reported home address and age group of the person vaccinated, as provided by the medical provider in the Illinois Comprehensive Automated Immunization Registry Exchange (I-CARE). “Up to date” refers to individuals who meet the CDC’s updated COVID-19 vaccination criteria based on their age and prior vaccination history. For surveillance purposes, up to date is defined based on the following criteria: People ages 5 years and older: · Are up to date when they receive 1+ doses of a COVID-19 vaccine during the current season. Children ages 6 months to 4 years: · Children who have received at least two prior COVID-19 vaccine doses are up to date when they receive one additional dose of COVID-19 vaccine during the current season, regardless of vaccine product. · Children who have received only one prior COVID-19 vaccine dose are up to date when they receive one additional dose of the current season's Moderna COVID-19 vaccine or two additional doses of the current season's Pfizer-BioNTech COVID-19 vaccine. · Children who have never received a COVID-19 vaccination are up to date when they receive either two doses of the current season's Moderna vaccine or three doses of the current season's Pfizer-BioNTech vaccine. This dataset takes the place of a previous dataset, which covers doses administered from December 15, 2020 through September 13, 2023 and is marked as historical: - https://data.cityofchicago.org/Health-Human-Services/COVID-19-Vaccinations-by-ZIP-Code/553k-3xzc. Data Notes: Weekly cumulative totals of people up to date are shown for each combination ZIP Code and age group. Note there are rows where age group is "All ages" so care should be taken when summing rows. Coverage percentages are calculated based on the cumulative number of people in each ZIP Code and age group who are considered up to date as of the week ending date divided by the estimated number of people in that subgroup. Population counts are obtained from the 2020 U.S. Decennial Census. For ZIP Codes mostly outside Chicago, coverage percentages are not calculated reliable Chicago-only population counts are not available. Actual counts may exceed population estimates and lead to coverage estimates that are greater than 100%, especially in smaller ZIP Codes with smaller populations. Additionally, the medical provider may report a work address or incorrect home address for the person receiving the vaccination, which may lead to over- or underestimation of vaccination coverage by geography. All coverage percentages are capped at 99%. Weekly cumulative counts and coverage percentages are reported from the week ending Saturday, September 16, 2023 onward through the Saturday prior to the dataset being updated. All data are provisional and subject to change. Information is updated as additional details are received and it is, in fact, very common for recent dates to be incomplete and to be updated as time goes on. At any given time, this dataset reflects data currently known to CDPH. Numbers in this dataset may differ from other public sources due to when data are reported and how City of Chicago boundaries are defined. The Chicago Department of Public Health uses the most complete data available to estimate COVID-19 vaccination coverage among Chicagoans, but there are several limitations that impact our estimates. Individuals may receive vaccinations that are not recorded in the Illinois immunization registry, I-CARE, such as those administered in another state, causing underestimation of the number individuals who are up to date. Inconsistencies in records of separate doses administered to the same person, such as slight variations in dates of birth, can result in duplicate records for a person and underestimate the number of people who are up to date. For all datasets related to COVID-19, please

NOTE: As of 2/16/2023, this page is no longer being updated. This table shows the number and percent of people that have initiated COVID-19 vaccination and are fully vaccinated by race / ethnicity and town. It includes people of all ages. All data in this report are preliminary; data for previous dates will be updated as new reports are received and data errors are corrected. A person who has received at least one dose of any vaccine is considered to have initiated vaccination. A person is considered fully vaccinated if they have completed a primary series by receiving 2 doses of the Pfizer, Novavax or Moderna vaccines or 1 dose of the Johnson & Johnson vaccine. The fully vaccinated are a subset of the number who have received at least one dose. Race and ethnicity data may be self-reported or taken from an existing electronic health care record. Reported race and ethnicity information is used to create a single race/ethnicity variable. People with Hispanic ethnicity are classified as Hispanic regardless of reported race. People with a missing ethnicity are classified as non-Hispanic. People with more than one race are classified as multiple race. A vaccine coverage percentage cannot be calculated for people classified as NH Other race or NH Unknown race since there are not population size estimates for these groups. Data quality assurance activities suggest that NH Other may represent a missing value. Vaccine coverage estimates in specific race/ethnicity groups may be underestimated as result of the exclusion of records classified as NH Unknown Race or NH Other Race. Town of residence is verified by geocoding the reported address and then mapping it a town using municipal boundaries. If an address cannot be geocoded, the reported town is used. Town-level coverage estimates have been capped at 100%. Observed coverage may be greater than 100% for multiple reasons, including census denominator data not including all individuals that currently reside in the town (e.g., part time residents, change in population size since the census) or potential data reporting errors. The population denominators for these town- and age-specific coverage estimates are based on 2014 census estimates. This is the most recent year for which reliable town- and age-specific estimates are available. (https://portal.ct.gov/DPH/Health-Information-Systems--Reporting/Population/Town-Population-with-Demographics). Changes in the size and composition of the population between 2014 and 2021 may results in inaccuracy in vaccine coverage estimates. For example, the size of the Hispanic population may be underestimated in a town given the reported increase in the size of the Hispanic population between the 2010 and 2020 censuses resulting in inflated vaccine coverage estimates. The 2014 census data are grouped in 5-year age bands. For vaccine coverage age groupings not consistent with a standard 5-year age band, each age was assumed to be 20% of the total within a 5-year age band. However, given the large deviation from this assumption for Mansfield because of the presence of the University of Connecticut, the age distribution observed in the 2010 census for the age bands 15 to 19 and 20 to 24 was used to estimate the population denominators. This table does not included doses administered to CT residents by out-of-state providers or by some Federal entities (including Department of Defense, Department of Correction, Department of Veteran’s Affairs, Indian Health Service) because they are not yet reported to CT WiZ (the CT immunization Information System). It is expected that these data will be added in the future. Caution should be used when interpreting coverage estimates for towns with large college/university populations since coverage may be underestimated. In the census, college/university students who live on or just off campus would be counted in the college/university town. However, if a student was vaccinated while study